FIGURE

Fig. 7

ID

ZDB-FIG-220725-13

Publication

Nunes et al., 2022 - RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition

Other Figures

All Figure Page

Back to All Figure Page

Fig. 7

Fig. 7. Identification of 3AP-prexasertib as a synergistic drug combination in neuroblastoma.

(A) IncuCyte live cell imaging indicates a drug synergism between RRM2 and CHK1 pharmacological inhibition resulting in reduced cell confluence in IMR-32 and CLB-GA neuroblastoma cells, while not affecting NIH3T3 confluence. (B) Combined 3AP-prexasertib treatment of IMR-32 and CLB-GA neuroblastoma cells leads to a significant induction of apoptosis compared to a single compound treatment or DMSO-treated cells, while NIH3T3 cells did not show any apoptotic response. (C) Combined 3AP-prexasertib treatment of IMR-32 and CLB-GA neuroblastoma cells results in a strong S phase arrest compared to a single compound treatment or DMSO-treated cells. (D) RT-qPCR analysis for the p53 targets CDKN1A and RRM2B as well as the proapoptotic genes BAX, NOXA, and PUMA upon combined 3AP-prexasertib treatment. (E) Immunoblotting for various DNA damage markers in IMR-32 and CLB-GA cells upon treatment with DMSO or 3AP or prexasertib as a single agent or combined 3AP and prexasertib (see quantification in fig. S2). (F) 3AP-prexasertib combined treatment synergistically affected neuroblastoma spheroid cell viability 120 hours after treatment.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Sci Adv